Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 414027, 9 pages
http://dx.doi.org/10.1155/2015/414027
Research Article

Successive Intramuscular Boosting with IFN-Alpha Protects Mycobacterium bovis BCG-Vaccinated Mice against M. lepraemurium Infection

1Unidad Académica de Ciencias Biológicas, Universidad Autónoma de Zacatecas, Avenida Preparatoria, S/N, Colonia Agronomicas, 98066 Zacatecas, ZAC, Mexico
2Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
3Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Carpio y Plan de Ayala, Colonia Santo Tomas, 11340 Mexico City, DF, Mexico

Received 3 March 2015; Accepted 16 July 2015

Academic Editor: Surendra Nimesh

Copyright © 2015 G. G. Guerrero et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. E. M. Fine, “Leprosy: what is being ‘eliminated’?” Bulletin of the World Health Organization, vol. 85, article 2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. N. Chakrabarty, S. G. Dastidar, A. Sen, P. Banerjee, and R. Roy, “Leprosy bacillus-possibly the first chemoautotrophic human pathogen cultivated in vitro and characterized,” Indian Journal of Experimental Biology, vol. 39, no. 10, pp. 962–983, 2001. View at Google Scholar · View at Scopus
  3. WHO, World Health Organization: Tuberculosis—Global Facts 2011/2102, WHO Stop TB Department, Geneva, Switzerland, 2012, http://www.who.int/tb/publications/2011/factsheet_tb_2011.pdf.
  4. A. Geluk, J. van der Ploeg, R. O. B. Teles et al., “Rational combination of peptides derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. leprae infection,” Clinical and Vaccine Immunology, vol. 15, no. 3, pp. 522–533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Geluk, K. Bobosha, J. J. van der Ploeg-van Schip et al., “New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy,” The Journal of Immunology, vol. 188, no. 10, pp. 4782–4791, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Rojas-Espinosa, “Murine leprosy revisited,” in Current Topics on the Profiles of Host Immunological Response to Mycobacterial Infections, pp. 97–140, Research Signpost, Kerala, India, 2009. View at Google Scholar
  7. R. L. Modlin, “The innate immune response in leprosy,” Current Opinion in Immunology, vol. 22, no. 1, pp. 48–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Rojas-Espinosa, K. Wek-Rodríguez, and P. Arce-Paredes, “The effect of exogenous peroxidase on the evolution of murine leprosy,” International Journal of Leprosy and Other Mycobacterial Diseases, vol. 70, no. 3, pp. 191–200, 2002. View at Google Scholar · View at Scopus
  9. L. B. Adams, M. T. Pena, R. Sharma, D. A. Hagge, E. Schurr, and R. W. Truman, “Insights from animal models on the immunogenetics of leprosy—a review,” Memorias do Instituto Oswaldo Cruz, vol. 107, no. 1, pp. 197–208, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Rambukkana, “How does Mycobacterium leprae target the peripheral nervous system?” Trends in Microbiology, vol. 8, no. 1, pp. 23–28, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Rojas-Espinosa, E. Becerril-Villanueva, K. Wek-Rodríguez, P. Arce-Paredes, and E. Reyes-Maldonado, “Palsy of the rear limbs in Mycobacterium lepraemurium-infected mice results from bone damage and not from nerve involvement,” Clinical and Experimental Immunology, vol. 140, no. 3, pp. 436–442, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. D. B. Young, “Leprosy lipid provides the key to Schwann cell entry,” Trends in Microbiology, vol. 9, no. 2, pp. 52–54, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. R. B. Oliveira, M. T. Ochoa, P. A. Sieling et al., “Expression of toll-like receptor 2 on human schwann cells: a mechanism of nerve damage in leprosy,” Infection and Immunity, vol. 71, no. 3, pp. 1427–1433, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. K. C. El Kasmi, J. E. Qualls, J. T. Pesce et al., “Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens,” Nature Immunology, vol. 9, no. 12, pp. 1399–1406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. N. van der Wel, D. Hava, D. Houben et al., “M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells,” Cell, vol. 129, no. 7, pp. 1287–1298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Gallucci, M. Lolkema, and P. Matzinger, “Natural adjuvants: endogenous activators of dendritic cells,” Nature Medicine, vol. 5, no. 11, pp. 1249–1255, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Fitzgerald-Bocarsly and D. Feng, “The role of type I interferon production by dendritic cells in host defense,” Biochimie, vol. 89, no. 6-7, pp. 843–855, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Decker, S. Stockinger, M. Karaghiosoff, M. Müller, and P. Kovarik, “IFNs and STATs in innate immunity to microorganisms,” Journal of Clinical Investigation, vol. 109, no. 10, pp. 1271–1277, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. M. G. Tovey, C. Lallemand, J.-F. Meritet, and C. Maury, “Adjuvant activity of interferon alpha: mechanism(s) of action,” Vaccine, vol. 24, no. 2, pp. S246–S247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Tam and M. J. Wick, “Dendritic cells and immunity to Listeria: TipDCs are a new recruit,” Trends in Immunology, vol. 25, no. 7, pp. 335–339, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. R. Aldridge, C. E. Moseley, D. A. Boltz et al., “TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 13, pp. 5306–5311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Lee, H. Li, M. T. Ochoa et al., “Integrated pathways for neutrophil recruitment and inflammation in leprosy,” Journal of Infectious Diseases, vol. 201, no. 4, pp. 558–569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Montoya, G. Schiavoni, F. Mattel et al., “Type I interferons produced by dendritic cells promote their phenotypic and functional activation,” Blood, vol. 99, no. 9, pp. 3263–3271, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Le Bon and D. F. Tough, “Type I interferon as a stimulus for cross-priming,” Cytokine and Growth Factor Reviews, vol. 19, no. 1, pp. 33–40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. E. Kohlmeier, T. Cookenham, A. D. Roberts, S. C. Miller, and D. L. Woodland, “Type I interferons regulate cytolytic activity of memory CD8+ T cells in the lung airways during respiratory virus challenge,” Immunity, vol. 33, no. 1, pp. 96–105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. T. H. M. Ottenhoff, “New pathways of protective and pathological host defense to mycobacteria,” Trends in Microbiology, vol. 20, no. 9, pp. 419–428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Ferrantini, M. Giovarelli, A. Modesti et al., “IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cell,” Journal of Immunology, vol. 153, no. 10, pp. 4604–4615, 1994. View at Google Scholar · View at Scopus
  28. M. S. Ernstoff, S. Fusi, and J. M. Kirkwood, “Parameters of interferon action. II. Immunological effects of recombinant leukocyte interferon (IFN-α2) in phase I-II trials,” Journal of Biological Response Modifiers, vol. 2, no. 6, pp. 540–547, 1983. View at Google Scholar · View at Scopus
  29. A. N. Theofilopoulos, R. Baccala, B. Beutler, and D. H. Kono, “Type I interferons (α/β) in immunity and autoimmunity,” Annual Review of Immunology, vol. 23, pp. 307–336, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Proietti, L. Bracci, S. Puzelli et al., “Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model,” Journal of Immunology, vol. 169, no. 1, pp. 375–383, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Geluk, “Biomarkers for leprosy: would you prefer T (cells)?” Leprosy review, vol. 84, no. 1, pp. 3–12, 2013. View at Google Scholar · View at Scopus
  32. F. D. Menozzi, R. Bischoff, E. Fort, M. J. Brennan, and C. Locht, “Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 21, pp. 12625–12630, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Prabhakaran, E. B. Harris, and W. F. Kirchheimer, “Binding of 14C-labeled DOPA by Mycobacterium leprae in vitro,” International Journal of Leprosy, vol. 44, no. 1-2, pp. 58–64, 1976. View at Google Scholar · View at Scopus
  34. P. Draper, “Purification of M. leprae. Annex 4 of report of the fifth meeting of the scientific working group on the immunology of leprosy (IMMLEP),” WHO Document TDR/IMMLEP-SWG(5)/80-3, WHO, Geneva, Switzerland, 1980. View at Google Scholar
  35. J. Chan, Y. Xing, R. S. Magliozzo, and B. R. Bloom, “Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages,” The Journal of Experimental Medicine, vol. 175, no. 4, pp. 1111–1122, 1992. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Luna-Herrera, I. Estrada-Parra, and O. Rojas-Espinosa, “Recognition of lipids antigens by the serum of mice infected with Mycobacterium lepraemurium,” International Journal of Leprosy and Other Mycobacterial Diseases, vol. 64, pp. 299–305, 1996. View at Google Scholar
  37. J. MacMicking, Q.-W. Xie, and C. Nathan, “Nitric oxide and macrophage function,” Annual Review of Immunology, vol. 15, pp. 323–350, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. T. J. Evans, L. D. K. Buttery, A. Carpenter, D. R. Springall, J. M. Polak, and J. Cohen, “Cytokine-treated human neutrophils contain inducible nitric oxide synthase that produces nitration of ingested bacteria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9553–9558, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Ischiropoulos, “Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species,” Archives of Biochemistry and Biophysics, vol. 356, no. 1, pp. 1–11, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Schön, R. Hernández-Pando, J. Baquera-Heredia et al., “Nitrotyrosine localization to dermal nerves in borderline leprosy,” British Journal of Dermatology, vol. 150, no. 3, pp. 570–574, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Silva-Miranda, K. W. Wek-Rodriguez, C. E. Martínez, and O. Rojas Espinosa, “Expression of cyclooxygenase-2, alpha 1-acid-glycoprotein and inducible nitric oxide synthase in the developing lesions of murine leprosy,” International Journal of Experimental Pathology, vol. 87, no. 6, pp. 485–494, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Hernández-Pando, T. Schön, E. H. Orozco, J. Serafín, and I. Estrada-García, “Expression of inducible nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis,” Experimental and Toxicologic Pathology, vol. 53, no. 4, pp. 257–265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. K. D. Mayer-Barber, B. B. Andrade, S. D. Oland et al., “Host-directed therapy of tuberculosis based on interleukin-1 and type i interferon crosstalk,” Nature, vol. 511, no. 7507, pp. 99–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. R. M. B. Teles, T. G. Graeber, S. R. Krutzik et al., “Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses,” Science, vol. 339, no. 6126, pp. 1448–1453, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. F. McNab, K. Mayer-Barber, A. Sher, A. Wack, and A. O'Garra, “The role of type I interferon in infectious disease,” Nature Reviews Immunology, vol. 15, pp. 67–103, 2015. View at Google Scholar